Stock A003220 DAEWON PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Daewon Pharmaceutical Co., Ltd.

Equities

A003220

KR7003220001

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-13 EDT 		5-day change 1st Jan Change
15,200 KRW +3.47% Intraday chart for Daewon Pharmaceutical Co., Ltd. +1.74% -2.94%
03-14 Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 SD Biotechnologies Co., Ltd. announced that it has received KRW 65 billion in funding from Koino Co.Ltd., Focus Asset Management Co., Ltd., Daewon Pharmaceutical Co., Ltd. CI

Business Summary

Daewon Pharmaceutical Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceutical products. The Company’s products include antipyretics, analgesics, anti-inflammatory drugs, respiratory drugs, gastrointestinal drugs, antimicrobial drugs, cardiovascular drugs, metabolic drugs, psychoneurotic drugs, neuromuscular drugs, endocrine drugs and others. The Company also produces multivitamins and health foods. The Company distributes its products within domestic market and overseas markets, including Vietnam, Myanmar, Southeast Asia, the Middle East and others.

Number of employees: 1,125

Sales per Business

KRW in Million2022Weight2023Weight Delta
Restrictions
95.0 %
452,801 94.6 % 500,696 95.0 % +10.58%
Health Functional Food
5.0 %
25,864 5.4 % 26,482 5.0 % +2.39%
Consolidated Adjustment
-0.1 %
-1,067 -0.2 % -521 -0.1 % -51.16%
Hearing Aid
0.1 %
1,286 0.3 % 295 0.1 % -77.04%

Sales per region

KRW in Million2022Weight2023Weight Delta
South Korea
98.0 %
467,170 97.6 % 516,427 98.0 % +10.54%
Overseas
2.0 %
11,715 2.4 % 10,526 2.0 % -10.15%

Managers

Managers TitleAgeSince
Seung-Yul Baek CEO
 Chief Executive Officer 65 -
Seung-Ho Baek CEO
 Chief Executive Officer 68 -
Tae-Hong Choi PSD
 President 67 -
Jonathan In Baek BRD
 Director/Board Member 40 13-12-31
Se-Il Son PRN
 Corporate Officer/Principal 55 12-12-31
Bong-Chul Cho PRN
 Corporate Officer/Principal 60 12-12-31
Joo-Il Kim PRN
 Corporate Officer/Principal 52 12-12-31
Han-Il Lim PRN
 Corporate Officer/Principal 61 10-12-31

Members of the board

Members of the board TitleAgeSince
Seung-Ho Baek CEO
 Chief Executive Officer 68 -
Seung-Yul Baek CEO
 Chief Executive Officer 65 -
Jonathan In Baek BRD
 Director/Board Member 40 13-12-31
Yong-Won Bang BRD
 Director/Board Member 65 20-03-23
Yeo-Won Son BRD
 Director/Board Member 65 -
Yong-Ju Park BRD
 Director/Board Member 70 -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 22,190,194 12,730,905 ( 57.37 %) 994,144 ( 4.480 %) 57.37 %

Shareholders

NameEquities%Valuation
Seung-Yul Baek
11.46 %
2,542,824 11.46 % 28 M ₩
Seung-Ho Baek
9.736 %
2,160,404 9.736 % 23 M ₩
In-hwan Baek
5.866 %
1,301,581 5.866 % 14 M ₩
DAEWON PHARMACEUTICAL CO., LTD.
4.480 %
994,144 4.480 % 11 M ₩
Jae-jin Yang
3.870 %
858,700 3.870 % 9 M ₩
Jonathan In Baek
3.612 %
801,581 3.612 % 9 M ₩
In-young Baek
2.953 %
655,303 2.953 % 7 M ₩
In-sung Baek
1.151 %
255,303 1.151 % 3 M ₩
In-Jae Baek
1.149 %
254,981 1.149 % 3 M ₩
Danagen Co. Ltd.
0.6172 %
136,958 0.6172 % 1 M ₩

Holdings

NameEquities%Valuation
DAEWON PHARMACEUTICAL CO., LTD.
4.48%
 994,144 4.48% 10,760,724 $

Company contact information

Daewon Pharmaceutical Co., Ltd.

386 Cheonho-daero Seongdong-gu

04808, Seoul

+

http://www.daewonpharm.com
address Daewon Pharmaceutical Co., Ltd.(A003220)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Daewon Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
15,200 KRW
Average target price
21,000 KRW
Spread / Average Target
+38.16%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
DAEWON PHARMACEUTICAL CO., LTD. Stock Daewon Pharmaceutical Co., Ltd.
-2.94% 236M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.37% 588B
JOHNSON & JOHNSON Stock Johnson & Johnson
-2.81% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.33% 326B
ABBVIE INC. Stock AbbVie Inc.
+5.46% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.83% 239B
NOVARTIS AG Stock Novartis AG
+9.93% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-6.95% 200B
AMGEN INC. Stock Amgen Inc.
+11.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-0.02% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A003220 Stock
  4. Company Daewon Pharmaceutical Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW